Tilray Brands, Inc. (TLRY) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in Tilray Brands (TLRY) by buying shares or fractional shares at any major US broker, through a cannabis-focused ETF that holds it, or as one holding in a thematic basket. Tilray is a diversified consumer-packaged-goods company spanning cannabis (medical and adult-use), craft beer and beverages, hemp-based wellness products, and distribution. The single most important thing to understand is that Tilray is a low-priced, speculative stock: its cannabis growth depends heavily on international medical markets (especially Germany) and on US and global legalization that has repeatedly disappointed, while its beverage arm gives it a real, revenue-generating business that most pure cannabis names lack.
TLRY stock price
As of 2026-07-14, Tilray Brands, Inc. (TLRY) last closed at $4.32, down 34.5% over the past year. Over the past 52 weeks it has traded between $4.31 and $21.00.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Tilray Brands, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Tilray Brands, Inc. (TLRY) do?
Tilray Brands, Inc. is a diversified consumer company best known for cannabis but now spanning four areas: cannabis (medical and adult-use, plus hemp-derived products) across Canada, Europe, and other markets; a large craft beverage business built through acquisitions of SweetWater, Breckenridge, and beer brands and breweries from Anheuser-Busch and Molson Coors; a wellness arm centered on hemp-based products; and a distribution segment. This makes Tilray unusual among cannabis names: it generates substantial real revenue from beer and drinks, giving it a foothold in regulated US consumer markets even where cannabis remains federally illegal. Its fiscal year ends May 31, so its reporting calendar differs from most companies.
The 2026 picture is mixed. In its third fiscal quarter (ended February 28, 2026), Tilray reported record net revenue of about $207 million with roughly 11% organic growth, driven by a 73% jump in international cannabis revenue and 43% growth in Germany, where medical cannabis access has expanded. The beverage segment, however, declined as the company took margin-focused actions and faced industry-wide softness, though it completed a cost-savings program (Project 420) worth about $33 million annually. Tilray held roughly $265 million in cash and marketable securities and expanded its medical platform with acquisitions like Lyphe in the UK and HelloMD in Canada. The stock trades at a very low absolute price, reflects continued net losses and share dilution, and the company had explored but paused a reverse stock split. Full fiscal-year 2026 results are due July 28, 2026.
What's driving Tilray Brands, Inc. (TLRY)?
1. International medical cannabis growth
Tilray's fastest-growing engine is international medical cannabis, especially Germany, where 2024 reforms expanded patient access. In fiscal Q3 2026 international cannabis revenue rose 73% and Germany grew 43%. Europe's regulated medical markets are larger and higher-margin than Canada's crowded adult-use market, so building leadership there, ahead of broader legalization, is central to the bull case and a key differentiator from Canada-only rivals.
2. Craft beverage scale and diversification
Through SweetWater, Breckenridge, and brands acquired from Anheuser-Busch and Molson Coors, Tilray is one of the larger US craft beer players. This gives it a real, cash-generating consumer business and distribution muscle that could one day carry cannabis-infused drinks if US law changes. The Project 420 program cut costs by about $33 million annually. The challenge is that craft beer volumes are soft industry-wide, which weighed on segment revenue recently.
3. Optionality on US legalization
Tilray is positioned to benefit if the US reschedules or legalizes cannabis or eases banking restrictions. Its beer distribution network, brand portfolio, and balance sheet could let it move quickly into a legal US THC market. This optionality is a major reason speculative investors hold the stock, but it is entirely dependent on policy that has repeatedly stalled, so it is a catalyst that may or may not arrive.
4. Cost discipline and balance-sheet management
Tilray has pushed cost savings (Project 420), pursued margin-focused actions in beverages, and kept roughly $265 million in cash and marketable securities. Management points to record revenue and positive adjusted EBITDA in recent quarters as evidence the model is improving. Turning that into consistent net profitability without further heavy share dilution is the central financial test, and progress here would materially change how the market values the stock.
What are the risks to Tilray Brands, Inc. (TLRY)?
The biggest risk is that Tilray remains unprofitable on a net basis and has repeatedly issued new shares, diluting existing holders, a major reason the stock trades at a very low absolute price. Cannabis legalization, the core long-term catalyst, has stalled in the US and moves slowly elsewhere, so the biggest addressable market may stay closed for years. The Canadian adult-use market is oversupplied and price-competitive, and the craft beer segment faces industry-wide volume softness. Currency swings affect large international sales, and the company relies on acquisitions that carry integration risk. The stock is highly volatile and speculative, sensitive to legalization headlines, and the company explored a reverse stock split to maintain its Nasdaq listing, a reminder of the low share price.
How is Tilray Brands, Inc. (TLRY) valued? (approximate, Jul 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Tilray Brands, Inc.'s investor relations page or your broker.
- Revenue trend: Record net revenue ~$207 million in fiscal Q3 2026 (ended Feb 28, 2026), ~11% organic growth, led by international cannabis; beverage revenue declined
- Profitability: Positive adjusted EBITDA in recent quarters, but generally net losses; sustained net profitability not yet established
- Balance sheet / liquidity: Roughly $265 million in cash, restricted cash, and marketable securities as of fiscal Q3 2026
- Share count / dilution: History of issuing new shares to fund acquisitions and operations, diluting holders; a reverse stock split was explored then paused
- Valuation: Very low absolute share price; valued on revenue and legalization optionality rather than current earnings
- Analyst sentiment: Mixed to cautious; bulls cite international cannabis and diversification, bears cite losses, dilution, and stalled legalization
These figures are approximate and tied to the asOf date; verify live numbers before acting, especially since full fiscal-year 2026 results are due July 28, 2026. Tilray is an unprofitable, speculative stock valued on revenue growth and legalization optionality rather than earnings, so traditional profit multiples do not apply. Watch net losses, share dilution, and cash burn closely.
Who competes with Tilray Brands, Inc. (TLRY)?
Canadian and global cannabis producers
Canopy Growth (CGC), Aurora Cannabis (ACB), and Cronos Group (CRON) are Tilray's closest Canadian-listed peers, competing in adult-use, medical, and international cannabis. Like Tilray, several have struggled with losses and dilution, and all are highly exposed to the pace of global legalization and the oversupplied Canadian market.
US multi-state cannabis operators
US-focused operators like Green Thumb Industries (GTBIF), Curaleaf, and Trulieve dominate legal state-level US THC markets that Tilray largely cannot enter federally. They are the players best positioned if US legalization arrives, and represent an alternative, more US-centric way to invest in the cannabis theme.
Craft beer and beverage companies
Through SweetWater, Breckenridge, and brands from Anheuser-Busch and Molson Coors, Tilray competes with craft brewers like Boston Beer (SAM) and the craft portfolios of majors such as Molson Coors and Anheuser-Busch. This beverage exposure is unusual for a cannabis company and diversifies Tilray beyond pure THC plays.
How to invest in Tilray Brands, Inc. (TLRY)
There are three common ways to get TLRY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so TLRY sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where TLRY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Tilray Brands, Inc. (TLRY)
Tilray is a diversified cannabis and craft-beverage company with growing international medical cannabis sales and a large beer business, but it remains unprofitable on a net basis, dilutes shareholders, and depends on uncertain legalization. It is a speculative, high-risk stock better suited to risk-tolerant investors.
Build a basket around TLRY with Walnut
Use Tilray Brands, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is TLRY a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is fast-growing international medical cannabis (especially Germany), a diversified craft-beer business, and upside if US legalization arrives. The bear case is ongoing net losses, repeated share dilution, a very low share price, and legalization that has stalled for years. Tilray is a speculative, high-volatility stock, so weigh it carefully against your risk tolerance.
What does Tilray Brands actually do?
+
Tilray is a diversified consumer company operating in four areas: cannabis (medical and adult-use) across Canada, Europe, and beyond; craft beer and beverages through brands like SweetWater and Breckenridge; hemp-based wellness products; and distribution. Unlike pure cannabis names, it earns substantial real revenue from beer and drinks, giving it a foothold in regulated US consumer markets even where cannabis is federally illegal.
Does Tilray pay a dividend?
+
No. Tilray does not pay a dividend. As an unprofitable, growth-focused company still investing in cannabis expansion and its beverage business, it reinvests cash rather than returning it to shareholders. Investors hold TLRY for potential capital appreciation tied to revenue growth and cannabis legalization, not for income. Do not expect any payout in the near term.
Why is Tilray's stock price so low?
+
Tilray trades at a very low absolute price for a few reasons: it has posted persistent net losses, it has repeatedly issued new shares to fund acquisitions (diluting existing holders and lowering per-share value), and the cannabis sector has broadly de-rated as legalization stalled. The low price is why the company explored a reverse stock split to help maintain its Nasdaq listing requirements.
How important is Germany to Tilray?
+
Germany is one of Tilray's most important growth markets. After 2024 reforms expanded medical cannabis access, Tilray's German revenue grew about 43% in fiscal Q3 2026, part of a 73% jump in international cannabis revenue. Europe's regulated medical markets are larger and higher-margin than Canada's, so leadership in Germany is central to Tilray's international growth story and a key differentiator.
What is Tilray's beverage business?
+
Tilray is one of the larger US craft beer companies, built by acquiring SweetWater and Breckenridge, plus beer brands and breweries from Anheuser-Busch and Molson Coors. This gives it real revenue, distribution reach, and consumer brands independent of cannabis. Recently the segment saw revenue decline amid industry-wide craft-beer softness, though a cost program (Project 420) cut about $33 million in annual costs.
How does Tilray depend on cannabis legalization?
+
Much of Tilray's long-term upside rests on legalization. Broader US reform (rescheduling, banking access, or full legalization) would open the large US THC market its beer distribution could serve, and looser rules abroad would expand medical and adult-use sales. But this policy has repeatedly stalled, so the catalyst is real yet uncertain, making the timing of any payoff hard to predict.
How can I get exposure to Tilray through an ETF?
+
TLRY appears in several cannabis-focused and marijuana-industry ETFs, where it is often among the larger holdings alongside peers like Canopy Growth and Aurora. ETF exposure spreads single-stock risk across many cannabis names but dilutes how much any Tilray move affects you. Always check a fund's holdings and weighting before assuming meaningful exposure to Tilray specifically.
What are the main risks of investing in TLRY?
+
The central risks are persistent net losses and share dilution, which have pushed the price very low, plus a stalled US legalization timeline that keeps the biggest market closed. The Canadian adult-use market is oversupplied and price-competitive, craft beer volumes are soft, currency swings affect international sales, and acquisitions add integration risk. The stock is highly volatile and speculative, moving sharply on legalization headlines.
When does Tilray report earnings?
+
Tilray's fiscal year ends May 31, so its calendar differs from most companies. Its fourth-quarter and full fiscal-year 2026 results are scheduled for release after market close on July 28, 2026. Because Tilray is a speculative, news-sensitive stock, quarterly reports on revenue growth, cash burn, and dilution tend to move the shares sharply, so the reporting dates are worth tracking.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Tilray Brands, Inc.'s investor relations page or your broker before making investment decisions.